Loading clinical trials...
Loading clinical trials...
TENecteplase in Central Retinal Artery Occlusion (TenCRAOS): A Prospective, randomized-controlled, double-dummy, double-blind phase 3 multi-centre trial of TNK 0.25 mg/kg + placebo vs. ASA + placebo (...
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Oslo University Hospital
NCT06861985 · Ocular Surface Disease, Central Retinal Artery Occlusion
NCT00802698 · Central Retinal Artery Occlusion
NCT02390245 · Glaucoma, Glaucoma Suspect, and more
NCT02483650 · Air or Gas Embolism, Carbon Monoxide Poisoning, and more
University Hospital Antwerp
Antwerp
University Hospital Leuven
Leuven
Aarhus University Hospital
Aarhus
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions